DNMT3B-COMMD7 Fusion FISH Probe
The DNMT3B-COMMD7 Fusion FISH Probe is used to confirm a fusion of the DNMT3B and COMMD7 genes. The fusion of the DNMT3B and COMMD7 genes has been associated with Uterine Carcinosarcoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| DNMT3B-COMMD7-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-RERE | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-REOR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-REGO | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-REGR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-OROR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GORE | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GROR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| DNMT3B-COMMD7-20-AQAQ | 20 (40 μL) | 200 μL |
|
DNMT3B Gene Summary
CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined. [provided by RefSeq, May 2011]
Gene Name: DNA Methyltransferase 3 Beta
Chromosome: CHR20: 31350190 -31397162
Locus: 20q11.21
COMMD7 Gene Summary
The COMM Domain Containing 7 (COMMD7) gene is located on chr20 :31290492-31331814 at 20q11.21.
Gene Name: COMM Domain Containing 7
Chromosome: CHR20: 31290492 -31331814
Locus: 20q11.21
Gene Diseases
The DNMT3B COMMD7 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Uterine Carcinosarcoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|